Welcome to our dedicated page for Guided Thera news (Ticker: GTHP), a resource for investors and traders seeking the latest updates and insights on Guided Thera stock.
Guided Therapeutics develops the LuViva Advanced Cervical Scan, a non-invasive cervical disease detection platform based on patented biophotonic technology. Company news centers on LuViva clinical-study updates, FDA application activity, and the device’s U.S. investigational status, along with financial-report developments and capital actions tied to common stock and warrants.
Recurring commercial updates include purchase orders, payments, shipments, and supply arrangements with Chinese medical-device distribution partners, including Hangzhou Dongye Medical Technology Company and Yuanshuo Medical Instruments Corporation. These announcements describe LuViva devices and single-use components, distributor relationships, and revenue recognition tied to received payments and product shipments.
Guided Therapeutics, Inc. (OTCQB: GTHP) has completed a final $750,000 payment to GPB Capital Holdings, LLC, concluding a cash and equity exchange agreement from January 16, 2020. This payment has eradicated $5,070,000 in liabilities from the Company's balance sheet, including the removal of GPB's security interests in its assets and setting warrants at a fixed price. CEO Gene Cartwright expressed satisfaction with this achievement, stating it will allow the company to focus on growth without substantial debt payments.
Guided Therapeutics (OTCQB: GTHP) announced a new purchase order worth $530,695 from its Chinese partner, Shandong Yaohua Medical Instrument Corporation (SMI). This order follows a larger existing order of $2.5 million. The new order indicates progress towards FDA approval of LuViva, expected in early 2022. Guided Therapeutics anticipates revenues from China to exceed $1 million in 2021. Cervical cancer remains a significant health issue in China, highlighting the potential market for their advanced detection technology.
Guided Therapeutics, Inc. (OTCQB: GTHP) has opened a new LuViva Reference and Training Center in Budapest, Hungary, in partnership with Newmars Technologies. This center aims to train European physicians on the use of LuViva, a device for early cervical disease detection. The CE Mark allows commercialization across 27 EU countries, reaching 229 million women. New clinical data will be published next year indicating LuViva's ability to detect cervical cancer earlier than traditional tests. The company anticipates significant device orders in 2021, bolstered by the ongoing Russian certification process.